The mad scientist who cloned Speez in the first test tube was baffled by the miraculous escape of the spores that spawned more of Speez. The slimy amoebas took notice of rejection; they seemed to thrive on it. Their advance behaved just like Mickey Mouse and the Sorcerer's Broom; the more it was attempted to smite them, the more they divided and multiplied. On they marched, sneering at Yahoo programmers. The Mega-Speez changed colors; from bright vomit orange to a "greyed out" version which was the most dangerous form of all - as it replicated itself thousand of times in a moment. The computers at Yahoo were all frozen under the onslaught, the programmers completely overwhelmed and undermanned. Rendered impotent. (to be continued)
BigT: Thanks for a sane discussion
and yes, I have Spezma on ignore, much good though it does.
Nothing I could find really proved or disproved the patent issue and the website clearly states that a phase III trial is underway with a special protocol assessment - and that the 1&2 combo trial on lymphedemia expects to reveal results the last half of 2014, which is an undisputed date, obviously. So I contacted info at vocal. We'll see if they respond, which I expect they will.
It's an important issue and it would be interesting to know for sure without going back through pages of fine print.
P.S. on Collategene: Here is something more, dated Feb, 2012 - and remember, VICL also has interest in the ischemic limb issue.:
start******The current pipeline for PAD is strong, with 43 molecules in various phases of clinical development. Due to there being no available option to treat CLI currently, most of the therapies in the pipeline are classified as FIC. includes potassium channel and chloride channel activators targeting Acute Limb Ischemia (ALI), which is the primary stage of PAD. The PAD therapeutic pipeline also includes autologous stem cell therapies and gene therapies targeting CLI. Ixmyelocel-T and Collategene are the two late-stage therapies which have received fast track designation. Thus, the strong PAD therapeutics pipeline indicates that in the future the PAD therapeutics market will witness the launch of various therapies with specific novel disease-modifying modes of action.******end
I'm not saying I know anymore than what I read, but right now, it's active and in late stage development.
Bit T: I thought about your last post, since Collategene was clearly listed in the pipeline. I looked up as much as I could find on how the patents might be affected just in case I missed something. (and I STILL could have missed something) (we small investors are the last to find info)
The "deal" could expire in 2020 but that is a long way off. Here is a snippet about the program and if I find more, I'll post it, but I don't think the patent is an issue right now:
start *****The market is set to witness patent expiration of various drugs.
However, the expected launch of novel first-in-class (FIC) therapies like autologous cell therapy (Ixmyelocel-T) and gene therapy (Collategene) in the late stage of forecast period and growing prevelance of disease would drive the PAD therapeutics market in the coming years.
Collategene, a gene therapy was earlier filed in Japan but recently AngesMG Inc. has withdrawn its NDA filling and would conduct more clinical trials to further evaluate the results. Collategene is under preparation for Phase III trial in the US and EU and would start by the end of the fourth quarter of 2011. ******end
Strange how the censors can immediately leap to act, but the programmers don't seem to get out of bed in the mornings for years and years.....
Once upon a time in the hinterland of Nova, there was a large, stagnant pool of darkness known as Somes. Somes was teeming with life, and one of the lesser species was known as Speez. Speez was a crafty clone of several other species grown in the test tubes of an underground laboratory along the banks of the Somes..........
(to be continued........)
Unless you can post a link to the "lost patent" info, I tend to discount the source. The info I posted came from their website, with dates imminent, not stale dates. I don't believe that even if their website needs updating, that they would use these dates if they had patent disruption. That would be a disclosure item of magnitude.
t is in the pipeline. But it is being developed by AnGes, who are responsible for the trials, the set up with SPA and the data, under an alliance with Vical using their DNA biotechnologies. It is shown on the website as such.
Asters Phase III This trial is also "still recruiting" patients, and the expected completion date is March 2017, still a long way off, and likely to be even longer as all patients data has to be considered - the trial was begun in 2013. Unless a miracle happens, no breath holding on this one.
Collategene (angiogenesis, Critical limb ischemic disease) is in good position on starting the phase III trial under AnGes alliance, which is exciting, if I were still excitable, since ischemia is a very unmet need. AnGes has reached an agreement with the FDA for the Special Protocol Assessment, a binding agreement that keeps everyone honest when assessing the data endpoints. It also has "Fast Track" status, which doesn't mean much, I have found to my sorrow when enthusiasm overloaded my sense.
AnGes is also underway with a phase 1/2 trial for Lymphedema, and THOSE results are expected in the last half of 2014. Which is NOW.
If anyone wants to read this, be prepared to help me defend the post from the expected and immediate onslaught from the Clone that resides here.
I know. But we couldn't even follow sensible posters because of this nitwit filling the entire board with his "grey out" nonsense after being ignored. That's actually Yahoo's fault for not somehow programming it more effectively.
I'm willing to let it drop. But if he PERSISTS, I'm ready to come back again with more for him. It's the only way.
Callme: Well, he wouldn't be much use there, that's for sure so that's out. Or in the cajones dept. either because he doesn't have any of those. But hark! I don't see any more messages from him so he must have filled the boiler position or gone elsewhere. Maybe to the Toilets#R#us board.
We are in receipt of Novaspeez/spas's outstanding resume and are doing our best.
While we have no position to fit him presently above ground, we recognize this kind of talent when we see it, and have created a new position just for him. It's called "Upside Down - the New Vision" and it's located to the far right of the boiler room. We would have put his name(s) on the door, but we ran out of room.
We also attempted to customize his desk but somebody keeps flushing it.
I think he locks himself in one of Yahoo's restrooms on his breaks and types away. (I was going to say "bangs away" but decided it might be a poor choice of words) Nothing else explains why Yahoo's Mr. Fix it men can't rewrite the "ignore" feature to function correctly.